1. A-family anti-inflammatory cyclopentenone prostaglandins: A novel class of non-statin inhibitors of HMG-CoA reductase.
- Author
-
Gutierrez LLP, Marques CV, Scomazzon SP, Schroeder HT, Fernandes JR, da Silva Rossato J, and Homem de Bittencourt PI Jr
- Subjects
- Animals, Humans, Male, Rats, Rats, Wistar, Anti-Inflammatory Agents chemistry, Anti-Inflammatory Agents pharmacology, Foam Cells enzymology, Hydroxymethylglutaryl CoA Reductases chemistry, Hydroxymethylglutaryl CoA Reductases metabolism, Hydroxymethylglutaryl-CoA Reductase Inhibitors chemistry, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Prostaglandins A chemistry, Prostaglandins A pharmacology
- Abstract
Disruption of the intracellular lipid balance leading to cholesterol accumulation is one of the features of cells that participate in the development of atherosclerotic lesions. Evidence form our laboratory indicates that anti-inflammatory cyclopentenone prostaglandins (cyPGs) of A- and J-family deviate lipid metabolism from the synthesis of cholesterol and cholesteryl esters to the synthesis of phospholipids in foam-cell macrophages. cyPGs possessing an α,β-unsaturated cyclopentane ring are highly electrophilic substances able to promptly react with reactive cysteines of intracellular molecules through Michael addition. On the other hand, HMG-CoA reductase (HMGCR), the enzyme responsible for the rate-limiting step in cholesterol biosynthesis, presents critically reactive cysteines at the entry of catalytic domain, particularly Cys561, that could be target of cyPG inhibition. In the present study, we showed that cyPGs (but not other non-α,β-unsaturated PGs) physically interact with HMGCR, in a dithiothreitol- and β-mercaptoethanol-sensitive way, and block the activity of the catalytic subunit of the enzyme (IC
50 for PGA2 = 0.17 μM). PGA2 inhibits HMGCR activity in cultured rat and human macrophages/macrophage-foam cells and leads to enhanced expression of HMGCR protein, as observed with statins. In cell culture models, PGA2 effectively inhibits the reductase at non-toxic doses (e.g., 1 μM) that block cell proliferation thus suggesting that part of the well-known antiproliferative effect of PGA2 may be due to its ability of blocking HMGCR activity, as cells cannot proliferate without a robust cholesterogenesis. Therefore, besides the powerfully anti-inflammatory and antiproliferative effects, the anticholesterogenic effects of PGA2 should be exploited in atherosclerosis therapeutics., Competing Interests: Declarations of competing interest All the authors declared no relevant relationships, conditions or circumstances, such as consultancies, financial involvement that could represent conflicts of interest. Dr. Homem de Bittencourt, Jr. reports, in addition, that he has a patent (LipoCardium: Endothelium-Directed Cyclopentenone Prostaglandin Liposomes; patent number PI0303598-0) issued by INPI (The Brazilian Patent Office) in Dec 1st, 2015. CNPq and FAPERGS (the funding organisms) had no involvement in the propositions presented in the present manuscript., (Copyright © 2021 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF